Business Context and Reporting Period
Apogee Therapeutics, Inc. (APGE) filed a Form 8-K on March 24, 2026, reporting the entry into a material definitive agreement. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Waltham, MA.
Key Financial Metrics and Transaction Details
This filing details a primary equity offering rather than operational financial results. Key transaction metrics include:
- Shares Issued: 5,000,000 shares of common stock.
- Offering Price: $70.00 per share.
- Over-Allotment Option: Underwriters exercised the full option to purchase an additional 750,000 shares on March 25, 2026.
- Total Shares Sold: 5,750,000 shares.
- Net Proceeds: Approximately $377.4 million (after underwriting discounts, commissions, and estimated offering expenses).
- Underwriters: Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated, and Guggenheim Securities, LLC.
The filing text does not provide current revenue, profit, cash flow, margins, or debt levels.
Material Changes
The material change reported is the significant increase in equity capital and share count resulting from the Offering. The Company expects the transaction to close on March 26, 2026. No prior comparable period financial data is provided in this specific filing to assess operational changes.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on operational outlook, or a discussion of risks beyond the standard indemnification clauses in the Underwriting Agreement. The Company agreed to indemnify the Underwriters against certain liabilities under the Securities Act of 1933.
Investor Verification Checklist
- Verify the final closing date of the Offering (expected March 26, 2026) and the actual net proceeds received.
- Review the Company's most recent 10-K or 10-Q to assess current cash burn rates and runway extension provided by the $377.4 million in proceeds.
- Confirm the post-offering share count and potential dilution impact on existing shareholders.
- Check for any lock-up agreements or restrictions on the sale of shares by existing management or major shareholders.